Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications

Affiliations

¹ Department of Medicine I Hematology and Oncology, Medical Center -University of Freiburg, Faculty of Medicine, Germany; Comprehensive Cancer Center Freiburg (CCCF), Medical Center -University of Freiburg, Faculty of Medicine.
² Clinical Trials Unit, Medical Center -University of Freiburg, Faculty of Medicine.
³ Comprehensive Cancer Center Freiburg (CCCF), Medical Center -University of Freiburg, Faculty of Medicine, Germany; Department of Orthopedics and Trauma Surgery, Medical Center -University of Freiburg, Faculty of Medicine.
⁴ Department of Medicine I Hematology and Oncology, Medical Center -University of Freiburg, Faculty of Medicine, Germany; Comprehensive Cancer Center Freiburg (CCCF), Medical Center -University of Freiburg, Faculty of Medicine. monika.engelhardt@uniklinik-freiburg.de.

Comment

Katja Schoeller et al. Haematologica. 2024.

. 2024 Apr 1;109(4):1279-1284.

doi: 10.3324/haematol.2023.283884.

¹ Department of Medicine I Hematology and Oncology, Medical Center -University of Freiburg, Faculty of Medicine, Germany; Comprehensive Cancer Center Freiburg (CCCF), Medical Center -University of Freiburg, Faculty of Medicine.
² Clinical Trials Unit, Medical Center -University of Freiburg, Faculty of Medicine.
³ Comprehensive Cancer Center Freiburg (CCCF), Medical Center -University of Freiburg, Faculty of Medicine, Germany; Department of Orthopedics and Trauma Surgery, Medical Center -University of Freiburg, Faculty of Medicine.
⁴ Department of Medicine I Hematology and Oncology, Medical Center -University of Freiburg, Faculty of Medicine, Germany; Comprehensive Cancer Center Freiburg (CCCF), Medical Center -University of Freiburg, Faculty of Medicine. monika.engelhardt@uniklinik-freiburg.de.

No abstract available

Figures

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.
Holler M, Ihorst G, Reinhardt H, Rösner A, Braun M, Möller MD, Dreyling E, Schoeller K, Scheubeck S, Wäsch R, Engelhardt M. Holler M, et al. Haematologica. 2023 Apr 1;108(4):1115-1126. doi: 10.3324/haematol.2022.281489. Haematologica. 2023. PMID: 36325890 Free PMC article.
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.
Mian H, McCurdy A, Giri S, Grant S, Rochwerg B, Winks E, Rosko AE, Engelhardt M, Pawlyn C, Cook G, Jackson G, Bringhen S, Facon T, Larocca A, Zweegman S, Wildes TM. Mian H, et al. Blood Cancer J. 2023 Jan 5;13(1):6. doi: 10.1038/s41408-022-00779-2. Blood Cancer J. 2023. PMID: 36599867 Free PMC article.

1. Larocca A, Dold SM, Zweegman S, et al. . Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32(8):1697-1712. - PubMed
1. Coulson AB, Royle K-L, Pawlyn C, et al. . Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open. 2022;12(6):e056147. - PMC - PubMed
1. Efficace F, Gaidano G, Petrucci MT, et al. . Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. Lancet Healthy Longev. 2022;3(9):e628-e635. - PubMed
1. Pawlyn C, Khan AM, Freeman CL. Fitness and frailty in myeloma. Hematol Am Soc Hematol Educ Program. 2022;2022(1):337-348. - PMC - PubMed
1. Scheubeck S, Ihorst G, Schoeller K, et al. . Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. Cancer. 2021;127(18):3422-3436. - PubMed